Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Turoctocog Alfa Pegol Action Pathway
Homo sapiens
Drug Action Pathway
Turoctocog alfa pegol is a version of turoctocog alfa also known as esperoct, used to treat hemophilia A. The difference between turoctocog alfa pegol and turoctocog alfa is the modification to the structure of turoctocog alfa pegol extends its half-life. It acts by replacing coagulation factor VIII which is deficient in patients with hemophilia.
References
Turoctocog Alfa Pegol Pathway References
Agerso H, Stennicke HR, Pelzer H, Olsen EN, Merricks EP, Defriess NA, Nichols TC, Ezban M: Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia. 2012 Nov;18(6):941-7. doi: 10.1111/j.1365-2516.2012.02896.x. Epub 2012 Jul 20.
Pubmed: 22812621
Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T, Rea C, Knobe K, Viuff D: Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013 Apr;11(4):670-8. doi: 10.1111/jth.12161.
Pubmed: 23398640
Lenting PJ, VAN Schooten CJ, Denis CV: Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007 Jul;5(7):1353-60. doi: 10.1111/j.1538-7836.2007.02572.x. Epub 2007 Apr 7.
Pubmed: 17425686
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings